Parents of children with rare diseases appealed this week to Europe’s lawmakers to approve proposals for encouraging clinical trials involving children. The call came at a conference in Brussels organised by the European Forum for Good Clinical Practice (EFGCP). Throughout Europe, 15 million children suffer from rare diseases, said Yann Le Cam from the European Organisation for Rare Diseases, yet almost no new medicines are being produced with them in mind. “In drug development, children come last,” he said.
Earlier, the conference had heard from European Commission official Peter Arlett about proposals – currently being considered by the European Parliament and the Council of Ministers – to encourage pharmaceutical companies to produce medicines specifically tested for babies and children.
“Children are not small adults,” said Ysbrand Poortman, Chairman of the European Platform for Patients’ Organisations and Industry. “Their bodies work differently. You can’t just take an adult dose, reduce it in proportion to the child’s size, and expect it do the same job.”
Fanny Senez | alfa
Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University
Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München
On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.
On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
27.02.2017 | Materials Sciences
27.02.2017 | Interdisciplinary Research
27.02.2017 | Life Sciences